TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

SYRCELT

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

SYRCELT

ST13

US500000079373376

Classe

1, 5, 42

Pedido

79373376

Registro

7592418

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

30

Atualização mais recente

03/04/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 42

Data de depósito

07/04/2023

Data de registro

10/12/2024

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

10/12/2024

Última transação

03/04/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

33

Localização do titular

BE

Examinador

MANCA, ALBERTO I

Unidade examinadora

L80

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

BePharBel Manufacturing S.A.

Representantes

Bradley M. Stohry Reichel Stohry Dean LLP

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Chemical products for use in the pharmaceutical industry, namely, chemical additives and preservatives for use in the manufacture of pharmaceuticals; active chemical ingredients for manufacture of pharmaceutical products for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical additives for use as binding agents in the manufacture of pharmaceuticals for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical carrier excipients for use in the manufacture of pharmaceutical preparations; chemical excipients for the manufacture of pharmaceutical preparations; raw material, namely, cellulose microspheres and microspheres made of cellulose, sugar, and starch for use in the manufacture of pharmaceuticals; microcrystalline cellulose microspheres for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, antioxidants and antimicrobials for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations; excipients for pharmaceutical preparation manufacture

Classe 5

Pharmaceutical products, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases, and pharmaceutical preparations for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents, namely, medicine release agents in the form of gastro-resistant and controlled release microparticles for the controlled release of active ingredients for a wide range of pharmaceutical products; drug delivery agents, namely, medicine delivery agents in the form of granulated powders for the controlled release of active ingredients for a wide range of pharmaceutical products; syrups for pharmaceutical use for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syrups being medicines for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syringes pre-filled with syrups for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines being esomeprazole for oral administration; medicines being omeprazole for oral administration; central nervous system stimulants; hormones for medical use; Pharmaceutical products for the treatment of gastrointestinal disorders; soporifics

Classe 42

Pharmaceutical research and development for the pharmaceutical industry; medical and pharmacological research services; research and development services relating to medicines; development of pharmaceutical preparations and medicines; development of pharmaceutical products

Publicações

Histórico de despachos e eventos da marca no USPTO.

30 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

31/05/2025

FICS

FINAL DISPOSITION NOTICE SENT TO IB

11/05/2025

FIMP

FINAL DISPOSITION PROCESSED

11/05/2025

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/03/2025

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

21/12/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

10/12/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

10/12/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

04/12/2024

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

04/12/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/09/2024

PUBO

PUBLISHED FOR OPPOSITION

10/09/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

21/08/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/08/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

07/08/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

07/08/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

07/08/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

07/08/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

22/07/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

22/07/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

22/07/2024

RFNT

REFUSAL PROCESSED BY IB

14/02/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

25/01/2024

RFRR

REFUSAL PROCESSED BY MPU

25/01/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

09/01/2024

CNRT

NON-FINAL ACTION WRITTEN

08/01/2024

DOCK

ASSIGNED TO EXAMINER

04/01/2024

NREP

NEW REPRESENTATIVE AT IB RECEIVED

08/09/2023

MAFR

APPLICATION FILING RECEIPT MAILED

11/07/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/07/2023

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

06/07/2023

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace SYRCELT ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.